Neomycin dosage and administration: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) m (→Hepatic Coma) |
Gerald Chi (talk | contribs) m (→Hepatic Coma) |
||
| Line 19: | Line 19: | ||
* Treatment should be continued over a period of five to six days during which time protein should be returned incrementally to the diet. | * Treatment should be continued over a period of five to six days during which time protein should be returned incrementally to the diet. | ||
* If less potentially toxic drugs cannot be used for chronic hepatic insufficiency, neomycin sulfate in doses of up to four grams daily may be necessary. The risks for the development of neomycin induced toxicity progressively increase when the treatment must be extended to preserve the life of a patient with hepatic encephalopathy who has failed to fully respond. Frequent periodic monitoring of these patients to ascertain the presence of drug toxicity is mandatory (see PRECAUTIONS). Also, neomycin serum concentrations should be monitored to avoid potentially toxic levels. The benefits to the patient should be weighed against the risks of nephrotoxicity, permanent ototoxicity and neuromuscular blockade following the accumulation of neomycin in the tissues.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NEO-FRADIN (NEOMYCIN SULFATE) SOLUTION [X-GEN PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea1d3e4-604a-4680-91e2-cce6a128a1b5 | publisher = | date = | accessdate = }}</ref> | * If less potentially toxic drugs cannot be used for chronic hepatic insufficiency, neomycin sulfate in doses of up to four grams daily may be necessary. The risks for the development of neomycin induced toxicity progressively increase when the treatment must be extended to preserve the life of a patient with [[hepatic encephalopathy]] who has failed to fully respond. Frequent periodic monitoring of these patients to ascertain the presence of drug toxicity is mandatory (see PRECAUTIONS). Also, neomycin serum concentrations should be monitored to avoid potentially toxic levels. The benefits to the patient should be weighed against the risks of nephrotoxicity, permanent ototoxicity and neuromuscular blockade following the accumulation of neomycin in the tissues.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NEO-FRADIN (NEOMYCIN SULFATE) SOLUTION [X-GEN PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea1d3e4-604a-4680-91e2-cce6a128a1b5 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 17:27, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Dosage and Administration
To minimize the risk of toxicity use the lowest possible dose and the shortest possible treatment period to control the condition. Treatment for periods longer than two weeks is not recommended.
Hepatic Coma
For use as an adjunct in the management of hepatic coma, the recommended dose is 4 to 12 grams per day given in the following regimen:
- Withdraw protein from diet. Avoid use of diuretic agents.
- Give supportive therapy including blood products, as indicated.
- Give NEO-FRADIN Oral Solution in doses of four to twelve grams of neomycin sulfate per day in divided doses.
- Treatment should be continued over a period of five to six days during which time protein should be returned incrementally to the diet.
- If less potentially toxic drugs cannot be used for chronic hepatic insufficiency, neomycin sulfate in doses of up to four grams daily may be necessary. The risks for the development of neomycin induced toxicity progressively increase when the treatment must be extended to preserve the life of a patient with hepatic encephalopathy who has failed to fully respond. Frequent periodic monitoring of these patients to ascertain the presence of drug toxicity is mandatory (see PRECAUTIONS). Also, neomycin serum concentrations should be monitored to avoid potentially toxic levels. The benefits to the patient should be weighed against the risks of nephrotoxicity, permanent ototoxicity and neuromuscular blockade following the accumulation of neomycin in the tissues.[1]
References
Adapted from the FDA Package Insert.